Fifty patients with non-cirrhotic portal fibrosis who were admitted to hospital because of upper gastrointestinal bleeding were randomly assigned to treatment with either oral propranolol given in doses that reduced the resting pulse rate by 25% (25 patients) or with a placebo (25 patients). One year after the start of the study 20 patients in the propranolol group and five patients in the placebo group were free from recurrent gastrointestinal bleeding (p<0-0001).
Introduction
Portal hypertension is a common clinical problem in developing countries. Apart from cirrhosis of the liver, one of the primary causes of portal hypertension in developing countries is portal fibrosis, which is largely due to schistosomiasis of the liver. In Harare, Zimbabwe, bleeding from oesophageal varices accounted for 27% of admissions to hospital in patients who presented with acute upper gastrointestinal bleeding. ' Acute gastric erosions 10 8 Previous episodes of bleeding:
Yes 14 16
Causes of portal fibrosis: Schistosoma mansoni ova (liver) 8 7 Schistosoma mansoni ova (stool/rectal snip) only Sixty patients fulfilled the criteria for admission. Four patients died within a few hours of admission before being entered into the study, and six refused to participate. The remaining 50 patients were entered into the study, which was approved by the ethical committee of the hospital. Forty eight hours after bleeding had stopped patients were randomly assigned by sealed envelope to the propranolol group (25 patients) or the placebo group (25 patients). The patients did not know which drug was being prescribed.
The two groups did not differ in age, sex, source of bleeding for which the patient was entered into the study, previous episodes of bleeding, causes of portal fibrosis, or results of biochemical tests (table) .
Propranolol was given orally twice a day in increasing doses until the resting pulse rate was reduced by 25%. The dosage ranged from 20 to 160 mg twice daily. The other 25 patients received two placebo tablets a day which resembled propranolol. 
Results
The resting pulse rate was significantly reduced in patients in the propranolol group (p<001). A 25% decrease from baseline rates was maintained throughout the trial (fig 1) . Among the 25 patients in the propranolol group five rebled, whereas 20 of 25 patients taking placebo rebled. The percentage of patients who were free of rebleeding at various times is shown in figure 2 . The difference between the propranolol group and the placebo group was highly significant (p<00001). The sources of rebleeding were analysed in relation to the original source of bleeding. In the propranolol group three patients rebled from varices and two patients from acute gastric erosions, the original source of bleeding having been ruptured varices in these five patients. In the placebo group, among the six patients whose initial source of bleeding was acute gastric erosions and who rebled, the site of rebleeding was ruptured varices in three and acute gastric erosions in the remaining three. Similarly, among the 14 patients whose original source of bleeding was ruptured varices, the site of rebleeding was acute gastric erosions in three and ruptured varices in 11.
There were six deaths-one in the propranolol group (bleeding varices) and five in the placebo group (four patients from bleeding varices and one patient from liver failure). There was no significant difference between the two groups (p>005).
Discussion
For years the only effective way of permanently reducing portal pressure in patients with oesophageal varices was portasystemic shunt surgery. The discovery by Lebrec et The results of this study showed no deterioration in liver or renal function. On the contrary, the feeling of wellbeing which is a well recognised side effect of this drug'0 was noted by many of our patients.
Fewer patients taking propranolol died than patients taking placebo, but the difference was not significant, perhaps because of the small number of patients who died and the short follow up period of one year. Appointing a colleague is rather like choosing a spouse, except that divorce is not really an option. In both cases you have to live with the consequences of your decision for several decades and you may mistakenly believe that you are in control, whereas in reality there is usually some mother in law like figure manipulating events. Do not be alarmed by this. Arranged marriages can be most successful because neither party has undue expectations of the other. Provided you can live with the other party the marriage can be made to work and your differences will lead to a stronger unit. My experience of seeing the NHS consultant appointments system in action may help show others how to, or not to, choose a colleague.
These comments apply only to senior NHS appointments. Academic posts should be subject to more liberal rules.
Preliminaries
The preliminaries take a long time, often a year or more in the case of a vacancy due to retirement. As soon as a close colleague whispers his or The details of the job description have to be discussed by the medical advisory committee of the relevant district hospital, often a consultant staff council. Make sure your friends are there; you may find that you don't have many on the day. If the chairman at least understands your case you may get your job description accepted with minor modifications. If the chairman does not then the matter will be deferred for a month, and then another month, and so on. If two districts are concerned your task is at least doubled. Eventually a job description must be agreed even though your secretary can spot the flaws. Keep a careful record of these discussions. Many months may yet elapse before the appointment, and during these months people will forget that they ever took place. They may assert later that they did not have the opportunity for comment. To avoid this it is important to ensure that all potentially interested parties see a copy of the job description.
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